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CHARACTERIZATION OF NIH-3T3 MOUSE FIBROBLAST
CELLS TRANSFECTED WITH THE SOMATOSTATIN
RECEPTOR SUBTYPE 2 AND THE PROTEIN
TYROSINE PHOSPHATASE SHP-1
Scott Bradford Cross, M.S.
Western Michigan University, 1999
The hormone Somatostatin (SMS) and its analogs have been shown to
mediate a variety of cellular actions including inhibition of cellular growth and
differentiation of endocrine tumors such as insulinomas and glucagonomas. The
mechanisms by which SMS exerts its antitumorigenic effects are poorly understood
but are thought to include one of the five Somatostatin receptors (SSTRl-5), and
the protein tyrosine phosphatase SHP-1. To determine if the antiproliferative
effects of SMS were due to the presence of the SSTR2 receptor or the stimulation of
SHP-1, we introduced cDNA's of the SMS receptor SSTR2, SHP-1, and a dominant
negative mutant of SHP-1 into NIH-3T3 cells by lipofection. Our research has
shown that the expression of the SSTR2 receptor and the SHP-1 gene product
controls cellular proliferation. We have also shown that both the SSTR2 receptor
and the SHP-1 gene product can control activation of MAPK proteins. Our results
also demonstrate that the SMS analog Sandostatin can control MAPK activation in
cells that express the SSTR2 receptor. We therefore conclude that SMS and its
analog Sandostatin have different modes of action within the NIH-3T3 mouse
fibroblast cell line.
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INTRODUCTION
Cancer is primarily caused by somatic mutations and it is an accumulation
of somatic mutations which creates cells that proliferate at rates well above their
norms and causes cells to lose the ability to control their own proliferation. Cancers
are established through mutations that lead either to the inactivation of tumor
suppressor genes such as p53 or the Retinoblastoma gene product Rb, or mutations
that result in a gain of function as in the oncogenes Ras or Raf. Usually it is a
combination of mutations, oncogenic events, and the inactivation of tumor
suppressor genes that leads to a loss of homeostatsis, as most cells in vivo require
more than one or two separate mutational events to generate a malignant phenotype
(Alison, 1997).
One form of cancer believed to be caused by separate mutational events is
pancreatic cancer. Forty percent of all patients diagnosed with pancreatic
adenocarcinomas have point mutations in the p 16 tumor suppressor gene ( Alison,
1997), and a loss of expression of the somatostatin receptor subtype 2 in exocrine
pancreatic carcinomas (Buscail et al., 1996). Pancreatic cancer is a debilitating
disease that generally is undetected until it is well advanced and not amenable to
treatment. It ranks I I th in incidence of all cancers within the United States yet, it is
our fifth leading cause of cancer deaths (Falk et al., 1988). Worldwide, pancreatic
affects slightly more men than women, and occurs more frequently in urban
I

2
areas than rural settings (Parkin and Muir, 1992). Environmental factors are
thought to play major roles in the etiology of the disease, however smoking has
continued to be the only proven risk factor, increasing the risk by two fold (NCI
website, January 1999).
The pancreas functions in producing enzymes that break down proteins and
fats as well as producing and secreting the hormones insulin, glucagon, and
somatostatin. Somatostatin (SMS) is a neuropeptide that was initially isolated as an
inhibitor of growth hormone and purified from sheep hypothalamus. Cells
producing SMS are found throughout the body in the central nervous system, the
peripheral nervous system, the gut and pancreas, as well as the thyroid, adrenals,
kidneys, and other essential organs (reviewed in Patel, 1995). It is known to inhibit
endocrine and exocrine secretions, modulate other neuropeptide and
neurotransmitter systems, and effect gastrointestinal motility, vascular smooth
muscle tone, intestinal absorption of nutrients and ions, and inhibit cellular growth.
SMS exists as two isoforms, one with 14 amino acids, SST-14, and its N
terminal extended form SST-28, both of which are cyclic (Figure 1) and coded for
by the same gene. A common precursor is produced and is differentially processed
to form the two isoforms that are associated with the same function yet are
differentially expressed in the tissues.
SMS has a short half-life of three minutes within the body and is therefore
not stable enough to treat a variety of neuroendocrine tumors and gastrointestinal
disorders. To improve upon the stability of SMS, analogs have been developed that

have longer half-lives yet still maintain the same effects as SMS. Most analogs are
designed as hexapeptides or octapeptides, but all maintain two essential amino

acids--number 8 and 9 (Tryptophan and Lysine)--which are necessary for biological
activity (Raynor et al., 1993). Most analogs also preserve amino acids number 7

(Tyrosine) and 10, which can be either a Threonine or a Valine (Table 1).

-------

SMS-14:

SMS-28:

Ala-Gly-Cy -Lys-Asn-Phe-Phe-T
i
r
Cys-Ser-Thr-Phe-Thr-Lys
Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys
Ala-Gly-Cys-Lys-Asn-Phe-Phe- rp
I
Jys-Ser-Thr-Phe-Thr-Lys

Figure 1. Amino Acid Sequence ofSMS-14 and SMS-28.

One ofthe analogs which has shown promise as a chemotherapeutic agent in

the treatment ofcancers is SMS 201-995 (tradename Sandostatin or Octreotide).

Sandostatin is an eight amino acid derivative ofSMS (Table 1) which has a Ki of
2. lnM for the SSTR2 receptor (Patel et al., 1994; Table 2), reaches peak plasma

concentrations after 30 minutes, and has a half-life of90 to 115 minutes (Waxman

et al., 1996).

Sandostatin has been shown to mediate the same wide variety ofeffects as

SMS (see below), and it possesses the ability to reduce tumor size either alone in
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patients with gastroenteropancreatic tumors and breast tumors (Weckbecker et al.,

1992) or in conjunction with other therapies such as Tamoxifen (Weckbecker et al.,

1994). However, it is now believed that it can only cause a reduction in tumors that
express the SMS receptor subtype 2 (SSTR2) (Buscail et al., 1994; Fisher et al.,

1996).

All five receptors belong to the G protein coupled receptor family and

exhibit the typical seven hydrophobic membrane spanning regions (Figure 2). They
are coded for by five genes located on separate chromosomes and are intronless

with the exception of the SSTR2 gene, which can give rise to the spliced variants
SSTR2-A and SSTR2-B in mice.

Table 1

Peptide

SMS Analogs
Tradename

SMS 201-995:

Sandostatin

BIM 23014:

Somatuline

RC-160:
MK.678:

Structure

Dphe-CYis-Phe-DTrp

Thr(ol)Jys-Thr-LJs

D�Nal-Cys-Tyr-DTrp
Thr-jys-Val-LJ

Dphe-Cys-Tyr-DTrp
Seglitide

Trp-Jys-Val-iys

(N-Me)-Tyr-DT

D, the D-isoform of amino acids; Nal, �-(2-nalphyl)alanine

F

Phe-Val-Lys

4

5
Table 2
Peptide Selective Binding Towards Human SMS Receptors
Ki (nM)
Peptide

SSTRl

SSTR2

SSTR3

SSTR4

SSTR5

SMS-14
SMS-28
Sandostatin
Somatuline
Seglitide

1.1
2.2
>1000
>1000
>1000

1.3
4.1
2.1
1.8
1.5

1.6
6.1
4.4
43
27

0.53
1.1
>1000
66
127

0.9
0.07
5.6
0.62
2

adapted from Patel, 1994
The Somatostatin receptors (SSTR's) do not share a high degree of sequence
specificity with other receptors except the opioid receptor family, for which there is
a 40% amino acid sequence similarity (Reisine, 1993). However, within
themselves, the five SSTR's do share a fairly high degree of specificity ranging
from 55% to 70% amino acid homology (Patel et al., 1995). Between species only
the SSTR2 receptor shows a high degree of sequence specificity of 93% to 98% for
human, pig, mouse, rat, and cow.
Sandostatin activity has been correlated with the high expression of the
SSTR2 receptor (Fujii et al., 1994). A serine (Ser305), located within
transmembrane domain 7, and a glutamine (Gln291), located within the 3rd
extracellular loop of the SSTR2 receptor, have been shown to confer the specificity
of Sandostatin for SSTR2 (Kaupman et al., 1995). Therefore, any cells, especially
tumors, shown to express the SSTR2 receptor might be a potential target for
treatment with the Sandostatin analog.

6
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Figure 2. A Schematic of the SSTR2 Receptor Based Upon Its Predicted Amino
Acid Sequence. Inset: predicted location of transmembrane-spanning regions
viewed from the extracellular surface of the receptor. CHO, Asparagine bound
carbohydrate. Darkened circles represent regions of the SSTR2 involved with
binding the SMS analog MK-678. Used with permission of Brenda Rauner,
Publications Manager and Executive Editor, The American Physiological Society,
4-30-99.
All of the SSTR's except SSTRl are coupled to G proteins (Bell and
Reisine, 1993; Rens-Domiano et al., 1992). G proteins are heterotrimers composed
of a, J3, and y subunits that mediate a wide variety of cellular actions. The
Ga subunit binds GTP upon receptor ligand binding and becomes activated. Once
activated, the heterotrimeric complex dissociates from the receptor and the GJ3y
complex stimulates its own set of downstream effectors. It is not clear as to
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whether the G protein complex separates upon dissociation from the membrane
(Clampham and Neer, 1993), however, it is known that both Ga and Gf3y subunits
remain active as long as GTP is bound to Ga. It is this cyclic association of GTP,
its hydrolysis to GDP and Pi, and the exchange of GDP which regulate the
functions of G proteins.
G proteins are classified based upon their activities and the relatedness of
their Ga subunits amino acid sequence. The Ga subunit possesses a GTPase
activity and contains a high affinity binding site for guanine nucleotides. Both the
Gf3 and Gy subunits have multiple isoforms which, depending upon the complex,
can be interchanged with each other (Schmidt et al., 1.992; Pronin and Gautam,
1992; Spring and Neer, 1994). The Gf3 subunits, of which there are three, appear
to be highly conserved (Simon et al., 1991), but the Gy subunits, of which there are
at least eight, show a range of sequence similarity of35% to 76% (Ray, 1995). It is
this heterogeneity that may contribute to the functional differences between
different Gf3y complexes.
Upon stimulation G proteins, and the receptors they are coupled to, have
been shown to mediate and/or stimulate signal transduction events which can act as
secondary messengers within the cell and control crucial cellular parameters. SMS
receptors have been shown to mediate membrane potential, cytosolic Ca+2 levels,
cellular differentiation, and cellular proliferation.
One of the most common pathways associated with cellular proliferation
and differentiation is the. MAPK pathway (reviewed in Seger, 1995). MAPK's are
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serine/threonine kinases which are part of a large family of proteins that include the
extracellular receptor kinases (ERK's), Jun N-terminal kinases (JNK's), stress
activated protein kinases (SAPK's) and p38 reactivating kinases (RK's). The
MAPK's become activated once they are phosphorylated at tyrosine and threonine
residues located within the kinase domain. Upon phosphorylation MAPK is
typically translocated to the nucleus where it can then phosphorylate its target
transcription factors.
Not much is known about how G protein coupled receptors activate
MAPK's but the process is believed to be similar to the receptor tyrosine kinases
(RTK's). It is thought that once a G protein coupled receptor binds to its ligand it
activates specific GJ3y complexes. GJ3y complexes are known to stimulate the
tyrosine phosphorylation of adapter proteins such as Src and Pyk2 which can then
bind and stimulate the proteins She, Grb2 and mSOS, which is a guanine nucleotide
releasing protein (GNRP) (van Biesen et al., 1995) The Grb2/mSOS complex
induces GDP-GTP exchange of Ras probably through plextrin homology domains
(Crespo et al., 1994), and then associates with the serine/threonine kinase Raf or
MAPKKK, phosphorylating it and thus activating it. Raf is known to activate
another serine/threonine kinase termed MEK, or MAPKK, which goes on to
phosphorylate the MAPK proteins (Figure 3). However, other pathways which
stimulate MAPK have been established. Pumigilia et al. (1995) has shown a direct
interaction between GJ3y subunits and the Raf-I serine-threonine protein kinase, and
Kranenberg et al., (1997) has shown that the Gi-mediated activation of the
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Ras/MAPK pathway involves a 100 kd tyrosine phosphorylated Grb2-SH3 binding
protein and not Src or She.

C ytoso l

~uoJeua
Trans,~rip li~n F~ctOrs
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Figure 3. A Possible Mechanism for MAPK Activation via G-Protein Coupled
Receptors.
Although stimulation of the MAPK pathway can be correlated with cellular
proliferation two groups have been able to show that SMS and its analogs, which
also stimulate the MAPK pathway, inhibit cellular proliferation. Bito et al., (1994)
have shown that SMS is capable of transiently increasing MAPK activity in
Chinese hamster ovary (CHO) cells transfected with the SSTR4 receptor, and that
this effect was mediated by a G protein due to its repression by pertussis toxin.
Yoshitomi et al., (1997) have been able to show a transient pertussis toxin
insensitive increase in MAPK activity in Min6 cells expressing the SSTR2 receptor.
SMS mediates its diverse effects by controlling the inhibition of adenylate cyc!ase
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(Liapi et al., 1986; Bito et al., 1994), hormone secretion, cellular proliferation
(Schalley, 1988; Viguerie et al., 1989), Ca+2 influx (Lewis et al., 1986; Fujii et al.,
1994), activation of protein tyrosine phosphatases (Liebow et al., 1989; Todisco et
+

+

al., 1995; Reardon et al., 1996), Na /lr exchangers (Hou et al., 1994), K channels
(Yamashita et al., 1987; Fosset et al., 1988), arachidonate release (Bito et al.,
1994), c-fos activity (Todisco et al., 1994) and mitogen activated protein kinase
(MAPK) activity (Bito et al., 1994 and Yoshitomi et al., 1997).
One possible way that SMS might be mediating its effects is through the
activation of one or more protein tyrosine phosphatases (PTPase). Liebolv et al.,
(1989) have been able to show that some of the SMS analogs, RC-160 and RC-121,
are able to stimulate PTPase activity in the human pancreatic cell line Mia PaCa-2.
In.contrast, the Sa.'1dostatin analog did not appear to be able to stimulate PTPase
activity or cause growth inhibition in this cell line. Buscail et al. (1994) have
shown that in NIH-3T3 cells as well as COS-7 cells Sandostatin does stimulate
PTPase activity as well as inhibit serum stimulated cellular proliferation when cells
express the SSTR.2 receptor, an effect that-dissipates when vanadate, a PTPase
inhibitor, is added.
To determine if a PTPase plays an active role in. the regulation of the SMS
signal through the SSTR2 receptor the SSTR2 gene from rat genomic DNA was
cloned and expressed in NIH-3T3 mouse fibroblast cells, which do not normally
express any of the SSTR receptors. cDNA's of the PTPase SHP-1, or a dominant
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negative mutant SHP-1 (C453S), were then transfected into NIH-3T3 cells which
expressed the SSTR2 receptor.
Once both cDNAs were shown to be expressed, the effects of the mutant
SHP-1 gene product on cellular proliferation were measured. This same experiment
was also performed by stimulating the clones with the Sandostatin analog.
MAPK activity was also determined to see if SMS stimulation was affecting
MAPK activity and if the signal was being regulated through the SHP-1 gene
product.

-

MATERIALS AND METHODS
General
All primers were synthesized and purchased from Only DNA. All
restriction endonucleases and enzymes were purchased from Life Technologies or
New England Biolabs unless otherwise stated. NIH-3T3 mouse fibroblast cells
were purchased from the American
• Type Culture Collection. SMS 201-995
(Sandostatin) was a generous gift from the Sandoz Pharmaceuticals Corporation.
Cloning of the SSTR2 Receptor
The SSTR2 receptor was cloned from Rat liver genomic DNA by the
polymerase chain reaction (PCR) using primers complementary to the 5' and 3' ends
of the SSTR2 receptor. These primers encompassed the whole coding region and
amplified a fragment of the predicted size, 1119 bp. This fragment was ligated
overnight at 14°C to the pCR2. l cloning vector (lnvitrogen), which contained the
ampicillin resistance marker. The clones were then selected for by ampicillin
resistance and whether or not they developed a blue color in the presence of
40mg/ml X-gal, and digested with restriction endonucleases to ensure the ligated
fragment had inserted into the plasmid in the correct orientation. This fragment was
then sequenced using a dideoxy method (T7 Sequenase version 2.0, Amersham) to
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ensure that the PCR amplification steps did not cause any mutations within the
coding sequence.
The SSTR2 receptor was then separated from the pCR2. l vector by
digestion with the restriction endonuclease EcoRI, and electrophoresis through a
low-melting point (LMP) agarose gel. The expected l 134 bp fragment was then
excised from the LMP gel, heated 65°Cfor 15 minutes and purified by
phenol/chloroform extraction, and ethanol (EtOH) precipitated using O. IM NaCl.
After digestion with EcoRl, the 5. 7 kb pTracer-CMV vector (lnvitrogen) was used
for ligation to the SSTR2 receptor fragment using T4 DNA Ligase (lnvitrogen)
overnight at 14°C.
Cloning of the SHP-1 and SHP-1 Dominant Negative Mutant PTPase
The SHP-1 cDNA and the SHP-1 dominant negative mutant (C453S) cDNA
were the kind gifts from Dr. Mathew Thomas, of Washington University in St.
Louis, Missouri. The SHP-1 dominant negative mutant (C453S) which has the
amino acid serine number 453 replaced with a cysteine within the catalytic domain
is catalytically inactive. The SHP-1 cDNA clone, its mutant, and the 5.4 kb
pcDNA3.1(+) vector (Invitrogen) were all digested with the restriction
endonuclease EcoRl giving a 2207 bp SHP-1 fragment, a 2207 bp mutant SHP-1
fragment, and a linearized pcDNA3.1(+) vector. These fragments were then
electrophoresed through a LMP agarose gel, excised from the LMP gel heated at
65°C for 15 minutes, purified by phenol-chloroform extraction, and EtOH
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precipitated using a 0. l M NaCl. Both SHP-1 fragments were ligated to the linear
pcDNA3. l(+) vector using T4 DNA Ligase (Invitrogen) and overnight ligation at
14° C.
Bacterial Transformation
Ligation reactions were mixed with DH5aF' chemically competent cells
(Life Technologies) and incubated on ice for 30 minutes. The mixture was heat
shocked for 30 seconds at 42°C and placed on ice for 2 minutes before 450µ1 of
SOC medium was added. The mixtures were then incubated at 37°C for 60 minutes
in a shaking incubator. After incubation the transformed cells were plated onto LB
agar which contained l 0g/L Bacto Tryptone, 5g/L Yeast Extract, 5g/L NaCl, 15g/L
agar, and 50mg/L ampicillin (Sigma). These plates were incubated overnight at
37°C. Individual colonies were used to inoculate LB broth supplemented with
50mg/L ampicillin at 37°C in a shaking incubator overnight.
Plasmid Purification
Small scale plasmid preparations were performed to purify the plasmids for
analysis by restriction endonuclease digestion. A 1.5ml bacterial broth culture was
grown overnight at 37°C in a shaking incubator and pelleted by centrifugation at
14,000 rpm for 1 minute. The supernatant was discarded and the pellet was
resuspended in residual medium and 350µ1 of microscreening buffer that contained
an isosmotic solution of8% sucrose, 50mM EDTA, 0.5% Triton X-100, and IOmM
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Tris-HCl (pH 8.0). This mixture was then vortexed for 20 seconds and 35µ1 of
10mg/ml lysozyme (Sigma) was added to the mixture before vortexing briefly and
incubating at 37°C. After the solution became viscous tubes were placed in a
boiling water bath for 1 minute and pelleted by centrifugation at 14,000 rpm for 5
minutes in order to pellet out the membranes and the genomic DNA To recover
the plasmid 30µ1 of 3M sodium: acetate was then added to the supernatant and
vortexed briefly. This was followed by the addition of 420µ1 ofisopropanol and
incubation at -20°C for 30 minutes. Centrifugation at 14, 000 rpm for 5 minutes
was used to pellet the DNA, and the pellet was then washed once with 100% EtOH
and allowed to air dry. Once dry, the pellet was resuspended in 200µ1 ofwater to
which 200µ1 of3M sodium acetate was then added. The solution was vortexed
briefly and 500µ1 of 100% EtOH was added and again vortexed briefly. The
mixture was then incubated at -20°C for 30 minutes, centrifuged at 14,000 rpm for
3 minutes, and washed with 100% EtOH and allowed to air dry. The pellet was
then resuspended in water and the plasmid was digested with different restriction
endonucleases to determine the presence ofthe appropriate DNA fragment and its
orientation.
Large scale plasmid preparations were performed in order to obtain
quantities ofpurified DNA for cellular transfections and probes for Northern blot
analysis. To begin, bacteria were grown in LB broth, see above, in baffled flasks
for 24-48 hours. The bacteria were then centrifuged at 4000 rpm for 10 minutes
and resuspended in a solution that contained 50mM glucose, 25mM Tris-HCI, and
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lOmM EDTA. A 118th volume of0.2M NaOH/1% sodium decodyl sulfate (SDS)
solution was then added and the contents were mixed and allowed to incubate at
room temperature for 5 minutes. A 4% volume of3M potassium acetate and 2M
glacial acetic acid solution was then added to precipitate protein, membrane
complexes, and genomic DNA. The sample was then vortexed and incubated on ice
for 10 minutes. The sample was then centrifuged at 4000 rpm for 15 minutes and
the supernatent was filtered. A 60% volume ofisopropanol was added, and the
sample was mixed and incubated at room temperature for 10 minutes. The sample
was then centrifuged at 5000 rpm for 15 minutes and the pellet was rinsed with 70%
EtOH and resuspended in water. A 33% volume of5M lithium chloride was then
added and the sample was centrifuged at 10,000 rpm for 10 minutes. An equal
volume ofisopropanol was then added to the supernatant and the sample was
centrifuged for another 10 minutes at 10,000 rpm. The pellet was then rinsed with
70% EtOH and resuspended in 100µ1 water. A 4µ1 aliquot ofRNAse A (Sigma)
was then added and the sample was allowed to incubate at room temperature for 30
minutes. A 5µ1 aliquot ofa 5% Cetyltrimethylammonium bromide (CTAB)
(Sigma) solution was then added and the mixture was allowed to incubate for 3
minutes before it was centrifuged for 5 minutes at 14,000 rpm. The pellet was then
resuspended in 300µ1 of1.2M sodium chloride and 750µ1 of100% EtOH was then
added. The sample was then placed at -20°C for 30 minutes before it was
centrifuged for 5 minutes at 14,000 rpm. The pellet was then rinsed in 70% EtOH
and allowed to air dry before being resuspended in water.
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The Wizard Plus minipreps and midipreps DNA purification systems
(Promega) were also used to purify plasmid DNA as per the instructions ofthe
manufacturer. Briefly, a bacterial culture was grown in 3-l00m! ofLB broth that
contained 50µg/ml ampicillin by shaking at 37°C. The broth culture was then
centrifuged to pellet the bacteria and resuspended in Cell Resuspension Solution
(50mM Tris-HCl (pH 7.5), lOmM EDTA, and lO0µg/ml Rnase A). The cells were
then lysed by the addition ofthe Cell Lysis Solution containing 0.2M NaOH and
1% SDS and briefly inverting the tubes several times. A Neutralization Solution
containing 1.32M potassium acetate was then added and also mixed by inversion
several times. The lysate was then centrifuged at 10,000 rpm for 5 minutes to pellet
bacterial proteins and membranes, and the supernatent was then mixed with a
Column Wash Solution (80mM potassium acetate, 8.3mM Tris-HCl (pH 7.5),
40µM EDTA, and 55% EtOH) and Resuspension Resin and passed through a
purification column. Purified DNA was then removed from the column by applying
50µ1 ofwater and briefly centrifuging.
Sequencing
Double stranded plasmid DNA was purified as described above and
determined to have a 260/280 ratio ofgreater than 1.7. A 20µ1 aliquot of2µg DNA
was-then denatured by adding 0.1 volumes of2M NaOH and 2mM EDTA and
incubation for 30 minutes at 37°C. The mixture was then neutralized by the
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addition of0. l volumes of3M sodium acetate (pH 5.2) and EtOH precipitated by
increasing the salt concentration to 0. lM NaCl and adding two volumes ofEtOH.
Sequencing was performed by using the Fidelilty DNA Sequencing System
(S7600-KIT, Oncor) according to the manufactures specifications. A total of5µg
ofDNA was added to a mixture containing 2µ1 Annealing Buffer (125mM Tris pH
8.5, l00mM MgCh, and 250mM NaCl) , lpmol ofprimer, and water to a final
volume of1 0µl. The primer and template were then annealed by heating for 2
minutes at 65°C, cooled to 35°C, and chilled on ice. A 3µ1 aliquot ofReaction
Buffer (0.4M Tris pH 8.5, 40mM MgCb, 40mM DTT, 0.4 mg/ml acetylated BSA,
4mM ATP, 1.5µM dTTP, 1.5µM dGTP, 1.5µM dCTP), T4 DNA polymerase , and
[a-35 S]-dATP (Dupont NEN Life Sciences) were then added to the annealing
mixture and water was used to make the final volume 18µ1. The mixture was then
at 40°C for 15 minutes and cooled on ice before 6µ1 ofT4 Accessory Mix was
added and aliquots of5.5 µl ofthe labeling reactions were then added to the
appropriate termination mixtures (C,A, T, and G), mixed, and incubated for 5
minutes at 40°C. The reactions were then stopped by addition ofStop Solution, the
Proteinase K solution, and incubation for another 15 minutes at 40°C. The samples
were then heated to 80°C for 5 minutes and loaded onto a 6% polyacrylamide
glycerol-tolerant buffered gel that contained 4.8g/ml urea and electrophoresed at 65
watts until the bromphenol blue indicator had been electrophoresed off the gel. The
gel was then fixed for 15 minutes in a 5% acetic acid and 15% methanol solution,
dried onto 3mm paper, and exposed to film.
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Transfection
NilI-3T3 cells were seeded onto 60mm tissue culture dishes of2 x 105
cells/dish and allowed to grow overnight in Dulbecco's Modified Eagles Medium
(DMEM, Life Technologies) supplemented with 10% calf serum (CS, Life
Technologies). To prepare a total of2µg of DNA was then added to 100µ1 ofOpti
MEM I Reduced Serum Medium (Life Technologies). A solution containing 10µ1
of Lipofectamine reagent (Life Technologies) and l00ul ofOpti-MEM I Reduced
Serum Medium was prepared and combined with the DNNOpti-MEM I complex.
While incubating at room temperature the cells were washed once in a phosphate
buffered saline (PBS; 137mM NaCl, 2.7mM KCl, 4.3 mM Na2HPO4·?H2O, and 1.4
mM KH2 PO4)) and then withOpti-MEM I Reduced Serum Medium. After a 45
minute incubation an 800µ1 aliquot was used to dilute the DNN lipofectamine
complex. This was then placed onto the cells and allowed to stand overnight at
37° C. The medium was then replaced with DMEM supplemented with 10% CS for
48 hours. After 48 hours, the respective antibiotics (400ug/ml G4 18 sulfate, Life
Technologies for selection of pcDNA3. 1 containing clones and 400ug/ml Zeocin,
Invitrogen, for selection of the pTracer containing clones) were added to the
medium for selection every 48 hours (or two to three weeks until only antibiotic
resistant colonies were seen growing on the plates. Once established, the selected
clones were taken off antibiotic selection and grown in DMEM supplemented with
10% CS. Antibiotic selection was occasionally reapplied to ensure that
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contamination of the cell lines was not occurring. Confirmation that clones which
survived the selection process expressed the inserted genes was performed by
northern blot analysis, and reverse transcription polymerase chain reaction (RTPCR).
RNA Isolation and Northern Blot Analysis
Cells were grown in 60mm tissue culture plates until they were 80% - 90%
confluent. The cells were then washed in PBS and 2ml of TRIZOL Reagent (Life
Technologies) was added to the culture dish and the cells were allowed to incubate
for 5 minutes at room temperature. The cell lysate was then transferred to a 1.6ml
centrifuge tube and 400µ1 of chloroform was added to the tube. The tubes were
then shaken and incubated at room temperature for 3 minutes before being
centrifuged at 12,000 rpm for 15 minutes at 4°C. The upper aqueous phase was
then removed and mixed with 1 ml isopropanol, incubated at room temperature for
10 minutes, and centrifuged at 12,000 rpm for 10 minutes at 4°C. The pellet was
suspended in 2ml of 75% EtOH, mixed, and centrifuged at 7000 rpm for 5 minutes
at 4°C. After partial drying the pellet was dissolved in 20µ1 diethylpyrocarbonate
(DEPC) treated water (Form 3796, Life Technologies, February 1997) and allowed
to incubate for 10 minutes at 55°C. The optical density (OD) of an aliquot of the
sample was then measured using spectrophotometric methods in order to determine
RNA concentration and purity.
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Five µg of RNA was glyoxylated by adding 20µ1 of a solution containing
342µ1 deionized glyoxal, 30 µl of lM NaPO4 (pH 6.7), 1.5ml dimethylsulfoxide
(DMSO), and 30µ1 of 10% SDS. The solution was then incubated at 50°C for 30
minutes. It was then loaded onto a 1% agarose GTG (FMC) gel containing a 1150th
volume of lM sodium phosphate (pH 6.8) and electrophoresed at 70 watts. The gel
was then soaked in water containing ethidium bromide, photographed, and the RNA
was transferred to a Durlon membrane (Stratagene) using a Rapid Downward
Transfer Turboblotter (Schleicher & Schuell).
Labeling of the probe was accomplished by placing 50ng of the purified
fragment in a tube. Five microliters of [a.-32P]dCTP (50uCi) was added to the

..

reaction. The volume was then adjusted to 50µ1 with water. This mixture was then
added to a Ready-To-Go DNA labeling Bead (Pharmacia Biotech) and incubated for
30 minutes at 37°C. Following incubation the reaction mixture was purified by a
Centricon filter (Micron Separations) to separate DNA with incorporated 32P from
unincorporated nucleotides. This was accomplished by adding the mixture to the
column and spinning the column for 5 to 15 minutes at 10,000 rpm. The purified
DNA was then washed three times with TE buffer (lOmM Tris-Cl pH 7.4, and 1
mM EDTA pH 8.0), and centrifuged briefly. The labeled probe(s) were then
analyzed by a liquid scintillation counter to determine their specific activity.
Prehybridization of the Duralon membrane was performed at 68°C in a
rolling Hybaid oven using a QuikHyb Hybridization Solution (Stratagene) for 1-2
hours. At least I x I 06 cpm of labeled probe was denatured by boiling in a water
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bath for 3 minutes along with 100µ1 of l0mg/ml sonicated salmon sperm (Sigma).
The mixture was then added to the prehybridization solution and incubated at 68°C
for at least 1 hour. The hybridization solution was disposed of and the membrane
was washed twice with a 2X SSC (0.2M CJisNa3O1, 3M NaCl), and 0.1% SDS
solution for 15 minutes each time. The membrane wa·s then washed with a 0.1X
SSC, 0.1% SDS solution at least once for 15 minutes. The membrane was then
allowed to air dry before wrapping in Saran Wrap (Dow) and autoradiopgraphed
(Kodak XAR 5 film) for at least 24 hours at -80°C. The film was then developed in
Developing Solution (Kodak) for 5 minutes, rinsed with cold water for 30 seconds,
fixed in Fixing Solution (Kodak) for 10 minutes, rinsed in cold water for 10
minutes, and allowed to air dry.
Reverse Transcription Polymerase Chain Reaction
A set of primers was created that were homologous to the 5' and 3' ends of
the SSTR2 receptor and the SHP-1 cDNA's to amplify the mRNA's of interest.
RNA was isolated as previously stated. In order to reverse transcribe the RNA into
cDNA 5µg of total cellular RNA was diluted into 18µ1 of water. It was then heated
at 90°C for 5 minutes in order to denature any secondary structure associated with
the RNA. It was then centrifuged briefly at 14,000 rpm and incubated on ice. A
cocktail consisting of 30U/µl AMV Reverse Transcriptase (Life Technologies), IX
AMV Reverse Transcriptase Buffer (Life Technologies), 40U/µl RNasin
(Promega), IO0µg/ml random hexamers (Life Technologies), 40mM dNTP's (Life
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Technologies), and water was added to the denatured RNA and the mixture was
allowed to incubate at 23°C for 10 minutes. The samples were then incubated at
42°C for 1 hour, 95°C for 10 minutes, and then chilled on ice.
PCR of the cDNA was optimized using the Opti-Prime PCR Optimization
Kit (Stratagene) which use 12 buffers, which vary in ·pH, magnesium concentration,
and potassium chloride concentration. These were placed into individual centrifuge
tubes along with 2µ1 of cDNA, and 45µ1 of a cocktail containing 400µM Master
Mix buffer (Stratagene), lOmM dNTPs, 2.5µg upstream primer, 2.5µg downstream
primer, and 30U of Taq DNA polymerase (Life Technologies). The PCR
conditions were 94°C for 3 minutes, 50°C for 2 minutes and allowed to proceed for
1 cycle, then PCR conditions of 72°C for 1.5 minutes, 94°C for 1 minute, and 50°C
for I minute was allowed to proceed for 30 cycles. To ensure nontemplated
addition of a polyadenylase tail an adenine nucleotide extension cycle of 72°C for
10 minutes was performed. The samples were then electrophoresed through a 1%
agarose gel.
Mitogen Activated Protein Kinase Assay
Cells were grown in 60mm tissue culture plates until they were 60-80%
confluent. Serum depleted medium (DMEM supplemented with I% CS) was then
added overnight and the cells were then incubated overnight at 37°C. The cells
were then treated with a 1 x 1o-<>M concentration of Sandostatin (Sandoz
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Laboratories), a concentration which has been shown to be an effective dose in
NIH-3T3 cells, or PBS for 5 minutes.
The p44/42 MAP Kinase Assay Kit (New England Biolabs) was used to
analyze all MAPK activation according to manufactures instructions. Briefly, all
cells were first washed once with ice-cold PBS before treatment with 0.5ml ofIX
Cell Lysis Buffer (20mM Tris HCI, pH 7.5, l50mM NaCl, I mM EDTA, 1mM
EGTA, 1% Triton, 2.5mM sodium pyrophosphate,lmM J3-glycerolphosphate, lmM
Na3 V04, lµg/ml leupeptin, and lmM PMSF and incubated on ice for 5 minutes.
The cells were then scraped with a rubber policeman into 1.6ml centrifuge tubes
and sonicated 4 times for 5 seconds each time at power level 5 with a sonic
dismembraner (Fisher Scientific). Lysates were centrifuged at 14,000 rpm for 10
minutes at 4°C and the supernatant was then stored at -80°C.
Total cellular protein was quantitated using the Bradford microassay
procedure (BioRad). Protein standards were made in 800µ1 ofwater and consisted
of 1-IOµg/ml bovine serum albumin (BSA, Sigma). Aliquots of2-5µ1 ofcellular
lysate were diluted to a final volume of 800µ1 and 200µ1 ofProtein Assay reagent
was added to the standards and samples, mixed, and allowed to incubate for 30
minutes. The standards and the samples were then aliquoted in triplicate onto a 96well plate and analyzed on a spectrophotometric plate reader at an absorbance of
595nm. A standard curve was constructed and sample concentrations were
determined by comparison to the curve.
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A standard amount oftotal protein (200µg) was incubated with 15ul of
resuspended Immobilized Phospho-p44/42 MAP Kinase (Thr202/Tyr204)
Monoclonal Antibody overnight at 4°C. The samples were then centrifuged for 30
seconds at 4°C and the pellet was washed twice with IX Lysis Buffer and twice
with IX Kinase Buffer (25mM Tris-HCl, pH 7.5, 5.mM 13-glycerolphosphate, 2mM
OTT, 0.lmMNa3VO4,and l0mMMgCh)
Aliqouts of50µ1 containing IX kinase buffer, IO0µM ATP and 2µg Elk-I
fusion protein were then added to the sample and allowed to incubate for 30
minutes at 30°C. The reaction was terminated with 25µ1 of3X SOS sample buffer
(62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50mM OTT, and 0.1%
bromphenol blue}, and boiled for 5 minutes, mixed, and centrifuged for 2 minutes at
14,000 rpm. The samples were then loaded onto a 6% SOS-PAGE gel and
electrophoresed at 100 watts until the dye marker was centered in the gel..
Protein was then transferred to a polyvinylidine flouride (PVDF) membrane
(Millipore) using Ideal turboblotter at 6 volts for 2-3 hours. The membrane was
then washed with 25ml IX tris-buffered saline (TBS) for 5 minutes at room
temperature. The membrane was then incubated overnight in 25ml blocking buffer
(lX TBS, 0.1% Tween-20, and 5% nonfat dry milk}, at 4°C. A PhosphoElk-1
Antibody (New England Biolabs) was added at a 1: I000 dilution to 10ml of
Antibody Dilution Buffer (IX TBS, 0.05% Tween-20, and 5% BSA) and incubated
with the membrane overnight at 4°C. The membrane was then washed 3 times in
15ml ofTBST (IX TBS and 0.05% Tween-20) for 5 minutes each time. It was then
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incubated with an HRP-conjugated anti-rabbit secondary antibody (1 :2000, New
England Biolabs) and an HRP-conjugated anti-biotin antibody (I: 1000, New
England Biolabs) in 10ml ofblocking buffer for 1 hour at room temperature. The
membrane was then washed 3 times in 15ml ofTBST for 5 minutes each.
In order to detect the proteins the membrane was incubated in 10ml of1X
LumiGLO reagent (New England Biolabs) for 1 minute at room temperature. The
membrane was then wrapped in Saran Wrap and exposed to film on three different
times ranging from 10 seconds to 5 minutes before being developed (see above).
Cell Growth Curves
Cells were initially plated at a density of5 x 104 cells/well in a 12-well
tissue culture plate containing 1ml/well serum depleted medium (DMEM
supplemented with 1% CS) and incubated over night at 37°C. The cells were fed
within 24 hours with either serum depleted medium or serum depleted medium
containing 1 x 10-6 M Sandostatin. At 48 hours post plating the wells from each
plate were washed once with 1ml IX PBS and then trypsinized with 1ml of
Trypsin-EDTA (Life Technologies). The cells were centrifuged for 3 minutes at
800 rpm and then resuspended in DMEM. The cells were then counted using a
hemocytometer to determine the number ofcells per ml. These experiments were
repeated three times. For each experiment three wells were counted per sample. A
total of9 wells were counted per sample.
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Statistics
Statistics for the cell counts included determination of analysis of variance
(ANOVA), and a comparisons of individual clones by a Tukey test (a.=0.05).
Statistics for the MAPK activation assays included an ANOVA, a split-split
replicated block, and student T-tests.
For the cell counts, the ANOVA was calculated using the Microsoft Excel
statistical analysis program. Because these results were not amenable to parametric
analysis the Tukey' s test, a non-parametric statistical test, was performed as
described (Zar, 1984). All statistical analysis used an a value of0.05.
For the MAPK activation assays, the ANOVA was also calculated using the
Microsoft Excel statistical analysis program. This data was also not amenable to
parametric analysis. Comparisons between treatment and non-treatment of the
clones was performed using a split-split replicated block analysis to determine if
there were differences between the clones and the Sandostatin treatment. Once a
difference was established a students T-test was run on the means of the clones to
determine exactly which clones were different from their controls. All statistical
analysis again used an a value of0.05.

RESULTS
Cloning of the SSTR2 Receptor
To clone the SSTR2 receptor we used a PCR reaction to amplify the gene
from rat genomic DNA by utilizing two PCR primers which were identical to the 5'
and 3' ends of the coding sequence of the rat SSTR2. Amplification using these two
primers resulted in a 1119 bp fragment which was ligated to the pCR2. l vector.
The ligation mixtures were used to transform chemically competent Escherichia
coli DH5a cells (see Materials and Methods). Restriction endonuclease digests of
the plasmids showed that two clones contained inserts of the correct length and
orientation (data not shown). These two clones were sequenced (see Materials and
Methods) and a clone that did not contain mutations within the coding sequence of
the SSTR2 receptor was selected and used in all future experiments.
To clone the SSTR2 receptor it was separated from the pCR2. l vector by
digestion of the plasmid with the restriction endonuclease EcoRI, gel purification,
and ligation into EcoRl digested pTracer vector. This ligation mixture was then
used to transform chemically competent DH5a cells. Restriction endonuclease
digests of a selected clone demonstrated that this clone did contain an insert of the
correct length and orientation (Figure 4).
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Cloning of the SHP-1 Gene
The 2207 bp protein tyrosine phosphatase SHP-1 cDNA and the mutant
SHP-1 (C453S) cDNA were ligated separately into the pcDNA3. l(+) vector at the

EcoR1 site located within the pcDNA3. l multiple cloning site (MCS). These
plasmids were then transformed into chemically competent DH5a. cells. Restriction
endonuclease digests of DNA from one clone showed that it contained an insert of
the correct length and orientation (Figure 4). One of the dominant negative mutant
clones was also sequenced to ensure that the clone contained theC453S mutation
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Figure 4. Restriction Endonuclease Digestions of the pTracer Vector+ SSTR2 and
the pcDNA3 .1(+) Vector+ SHP-1. 20µg of pTracer+ SSTR2 DNA or
pcDNA3.1(+)+ SHP-1 was digested with the restriction endonuclease EcoRI for 60
minutes at 37°C. 20µ1 of diluted DNA was loaded into each lane and
electrophoresed on a 1% agarose gel.
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Transfections ofNIH-3T3 Mouse Fibroblasts
Transfections were accomplished using a liposome technique as described
above. The plasmid DNA was allowed to incubate with the Lipofectamine reagent
to form micelles and then incubated with the cells in a serum free medium
overnight. After media replacement the cells were allowed to grow for 48 hours
before media containing serum and antibiotics were added for the selection process.
G418 Sulfate was the antibiotic used for clones which had been transfected with the
plasmid derived from the pcDNA3.1(+) vector, and Zeocin was the antibiotic used
for cells that were transfected with the plasmid derived from the pTracer-CMV
vector (see materials and methods). Cells that were transfected with both vectors
received a combination of both G418 Sulfate and Zeocin for selection.
The cells were allowed to grow in the medium containing serum and
antibiotics until several colonies appeared to be well established (approximately
two to three weeks). These colonies were then trypsinized off the plates using
cloning cylinders, and plated onto tissue culture plates. Table 3 describes all the
clones that were used and which cDNA's were transfected into them.
Characterization of the Transfected NIH-3T3 Cells
To determine if antibiotic resistant clones were expressing the genes of
interest, RNA produced from these constructs was analyzed by Northern blotting.
Hybridization with 32P-labelled SSTR2 and SHP-1 cDNA fragments were
performed to determine the relative expression levels for these genes, which show a

31
range of expression levels. Autoradiographs show that clones 4B and 4C both
express the SSTR2 cDNA and the mutant SHP-1 cDNA. Clone 4B expresses the
mutant SHP-1 at a much higher level than does clone 4C (Figure 5). Clone 4B also
shows a higher level of expression of the SSTR2 cDNA than does clone 4C (Figure
6). Clone 5A shows a slight expression of the wild-type SHP-1 protein (Figure 7)
and a high level of expression of the SSTR2 receptor (Figure 8).
Table 3
Description of the Transfected Cells (Clones)
Clone Number

Transfected cDNA(s)

1

SSTR2 ligated to the pTracer vector

2

Dominant Negative Mutant (DNM) SHP-1 Phosphatase
ligated to the pcDNA3.1(+) vector

3

Wild-Type SHP-1 Phosphatase ligated to the
pcDNA3 .1(+) vector

4B

SSTR2 ligated to the pTracer vector and DNM SHP-1
Phosphatase ligated to the pcDNA3.1(+) vector

4C

SSTR2 ligated to the pTracer vector and DNM SHP-1
Phosphatase ligated to the pcDNA3.1(+) vector

5

SSTR2 ligated to the pTracer vector and Wild-Type
SHP-lPhosphatase ligated to the pcDNA3.1(+) vector

6

pTracer vector only

7

pcDNA3.1(+) vector only

8

pTracer vector and pcDNA3.1(+) vector
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Figure 5. Autoradiograph of Northem Blot Probed With SHP-1 cDNA. Lanes 1-4
are clones 4B, C, D, and E which were transfected with both the SSTR2
receptorand the dominant negative mutant (DNM) SHP-1 phosphatase cDNA's.
Sµg of total RNA was glyoxylated and electrophoresed through a 1% GTG-agarose
gel and transferred to Duralon. The Northern blot was then probed with lx106
counts/ml 32P-labelled SHP-1 cDNA and washed under stringent conditions. The
autoradiogram was exposed for 24 hours at -80°C.
Analysis of Cellular Proliferation
To determine what affect the SSTR2 receptor and the SHP-1 protein would
have on the growth rates of the different clones, cells were grown in 12-well tissue
culture plates and counted as described in Material and Methods. The clone that
was transfected with only the SSTR2 receptor cDNA (clone 1) showed a growth
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Figure 6. Autoradiograph ofNorthern Blot Probed With SSTR2. Lanes 1-4 are
clones 4A, B, C, and D which were transfected with the SSTR2 receptor and the
dominant negative mutant (DNM) SHP-1 phosphatase cDNA's. 5µg of total RNA
was glyoxylated and electrophoresed through a I% GTG-agarose gel and
transferred to Duralon. The Northern blot was then probed with I xl 06 counts/ml
32P-labelled SHP-1 cDNA and washed under stringent conditions. The
autoradiogram was exposed for 24 hours at -80°C.
rate that was 32% ofthe control NIH-3T3 cell line (Figure 9), and was significantly
different from the control cell line as the calculated q-value of9.57 was greater than
the critical q-value of4.735 with an a-value of0.05. Clone 2, which was
transfected with the dominant negative mutant SHP-1 phosphatase cDNA showed a
growth rate of62% ofthe NIH-3T3 control cells and was significantly different
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Figure 7. Autoradiograph ofNorthem Blot Probed With Wild-Type SHP-1
Phosphatase. Lane 1 is clone 4A, which was transfected with the SSTR2 receptor
and the dominant negative mutant (DNM) SHP-1 phosphatase cDNA, and lane 2 is
clone SA, which was transfected with the SSTR2 receptor and the wild-type SHP-1
phosphatase cDNA. Sµg oftotal RNA was glyoxylated and electrophoresed
through a 1% GTG-agarose gel and transferred to Duralon. The Northern blot was
then probed with lx106 counts/ml 32P-labelled SHP-1 cDNA and washed under
stringent conditions. The autoradiogram was exposed for 24 hours at -80°C.
from the control cells as the calculated q-value of5.37 was greater than the critical
q-value of 4.735 with an a-value of0.05. Clone 3, which was transfected with the
wild-type SHP-1 phosphatase cDNA showed a growth rate of124% ofthe NIH3T3 control cells and therefore showed no effect on cellular proliferation as the
calculated q-value was less than the critical q-value. The clones that expressed both
the SSTR2 receptor cDNA and the dominant negative mutant SHP-1 phosphatase
cDNA (clones 4B and 4C) showed decreased growth rates when compared to the
control cells. Clone 4B, which expressed the SSTR2 receptor at higher levels, grew
at rates just greater than 43% ofthe controls while clone 4C, which expressed the
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Figure 8. Autoradiograph ofNorthern Blot Probed With the SSTR2 cDNA. Lane 1
is clone 1 which was only transfected with the SSTR2 receptor cDNA. Lane 2 is
clone 2 which was only transfected with the dominant negative mutant (DNM)
SHP-1 phosphatase cDNA. Lane 3 is clone 3 which was transfected with the wild
type SHP-1 phosphatase cDNA. Lane 4 is clone 4 which was transfected with both
the SSTR2 receptor and the dominant negative mutant (DNM) SHP-1 cDNA's.
Lane 5 is clone 5 which was transfected with both the SSTR2 receptor and the wild
type SHP-1 cDNA's. Lanes 6,7, and 8 are clones 6,7, and 8 respectively. Clone 6
was only transfected with the pTracer vector. Clone 7 was only transfected with the
pcDNA3.1(+) vector, and clone 8 was transfected with both the pTracer and the
pcDNA3.1(+) vectors. 5µg oftotal RNA was glyoxylated and electrophoresed
through a 1% GTG-agarose gel and transferred to Duralon.. The Northern blot was
then probed with lx106 counts/ml 32P-labelled SSTR2 cDNA and washed under
stringent conditions. The autoradiogram was exposed for 24 hours at -80°C
SSTR2 receptor at much lower levels, had a growth rate of97% compared to NIH3T3 control cells. Clone 4B was statistically different from the control cells as the
calculated q-value of8.02 was greater than the critical q-value of4.735 with an
a-value of0.05. Clone 4C was found to have no effect on cellular proliferation
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when compared to the untreated NIH-3T3 control cells as the calculated q-value
was less than the critical q-value with an a-value of 0.05.
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Figure 9. Cellular Proliferation of Clones. Reported as Percent of Control.
Cellular proliferation assays were replicated three times. Cells were plated at initial
densities of 50,000 cells/well and counted at 48 hours post plating using a
hemocytometer. Cell number represents an average of three replicates. Blue bars
represent clones that were not treated with Sandostatin. Red bars represent cells
that were treated with Sandostatin (Ix 10-6M).
Clone 5, which was transfected with the SSTR2 receptor cDNA and the
wild-type SHP-1 phosphatase cDNA, showed a growth rate equal to 36% of the
control NIH-3T3 cells, and was significantly different from control cells as the
calculated q-value of 8.94 was greater than the critical q-value of 4. 735 with an
a-value of 0.05. Clone 6, which was transfected with only the pTracer vector, and
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clone 8, which was transfected with both the pTracer and pcDNA3. l(+) vectors,
both showed reduced growth rates of48% and 44% respectively when compared to
the control NIH-3T3 cells, and were both found to be significantly different from
the control cells as their calculated q-values of7.34 and 5.34 respectively were both
greater than the critical q-value of4.735 with an a-value of0.05. This is in sharp
contrast to clone 7 which was transfected with only the pcDNA3. l(+) vector and
showed a growth rate equal to 84% ofthe control NIH 3T3 cells. Clone 7 was
found to have no effect on cellular proliferation when compared to the NIH-3T3
control cells as its calculated q-value was less than its critical q-value.
Treatment ofthe cell lines with the analog Sandostatin showed no affect on
the growth rates ofany ofthe clones. However, clone 1, which was transfected
with only the SSTR2 receptor cDNA, and clone 5, which was transfected with the
SSTR2 receptor and the wild-type SHP-1 phosphatase cDNA's, were both found to
be significantly different from the NIH-3T3 control cells as their calculated q
values of5.91 and 5.93 respectively were greater than the critical q-value of4.735
with an a-value of0.05.
Determination ofMAPK Activation
To determine ifactivation ofMAPK was affected by any ofthe clones or
treatments, MAPK activation assays were performed as described in the Materials
and Methods. The cells were either not treated or treated with Sandostatin (Figures
10 and 11). In the untreated cells (Figures 10 and 12) clone 1, which was only
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Figure 10. Western Blot of MAP Kinase Activation of Untreated Total Cellular
Protein. 200µg total cellular protein was analyzed for MAPK activation using the
p44/42 MAP Kinase Assay Kit (New England Biolabs) and electrophoresed
through a 6% SDS-PAGE and transferred to a PVDF membrane. Proteins were
detected using chemiluminescence. Densitometry was performed on a Kodak
imaging system.
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as Percent of Control ofNIH-3T3 cells. Percent control represents an average of 3
replicates.
transfected with the SSTR2 receptor cDN•..\, depleted MAPK activity to below
background levels and was therefore undetectable and significantly different than
the untreatedNlli-3T3 control cells as it had a p-value of 0.009 with an a-value of
0.05. Clone 2, which was transfected with only the dominant negative mutant SHPl phosphatase cDNA, decreased MAPK activity to approximately 62% of the
control cells and was found to have no effect on MAPK activation as its p-value
was 0.1 with an a-value of 0.05. Clone 3, which was transfected with only the
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wild-type SHP-1 phosphatase cDNA, showed a slight increase in MAPK activity to
106% of the untreated NIH-3T3 control cells and was determined to have no effect
on MAPK activation as the p-value was0.8 with an a-value of0.05.
Both of the clones which were transfected with the SSTR2 receptor cDNA
and the dominant negative mutant SHP-1 phosphatase cDNA, clones 4B and 4C,
had decreased MAP kinase activity, but to different levels. Clone 4B decreased
MAPK activity to approximately 26% of the untreated NIH-3T3 control cells and
was found to be significantly different with a p-value of0.0447 at an a-value of
0.05. Clone 4C, which expressed the SSTR2 receptor at lower levels than did clone
4B, decreased MAPK activity to 53% of the untreated NIH-3T3 control cells and
was determined to have no effect on MAPK activation as its p-value was0.096 with
an a-value of0.05. Clone SA, which was transfected with both the SSTR2
receptor cDNA and the wild-type SHP-1 phosphatase cDNA, showed a decrease in
MAPK activity equal to86% of the untreated NIH-3T3 control cells and was found
to have no effect on MAPK activation as its p-value was0.09 at an a-value of0.05.
The only other clone that was shown to decrease MAPK activation was clone 6
which was transfected with only the pTracer vector. This clone showed a decrease
in MAPK activity that was slightly greater than 53% of the untreated NIH-3T3
control cells and was found to be significantly different than the control cells as its
p-value was0.0221 at an a-value of0.05. Clone 7, which was transfected with the
pcDNA3. l(+) vector, and clone8, which was transfected with the pTracer vector
and the pcDNA3. l(+) vector, both showed activated MAPK levels that were
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approximately 92% and 97% respectively ofthe untreated NIH-3T3 control cell
line. Neither ofthese clones were found to have an effect on MAPK activation as
their p-values were 0.585 and 0.812 respectively, at an a-value of0.05.
Clones that were treated with the SMS analog Sandostatin showed different
levels ofMAPK activation than did the clones which were not treated with the
analog (Figure 13). Clone 1, which was transfected with only the SSTR2 receptor
cDNA, increased MAPK activity to 59% ofthe treated NIH-3T3 control cells.
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Clone 2, which was transfected with only the dominant negative mutant SHP-1
phosphatase cDNA, decreasedMAPK activity to approximately 46% of the treated
NIH-3T3 control cells. Overall, all other clones only decreasedMAPK activity by
2-10% except for clone 8, which was transfected with both the pTracer vector and
the pcDNA3. l(+) vector, which showed a decrease ofMAPK activation equal to
55% of the treated NIH-3T3 control cells. All of the clones treated with
Sandostatin were found to have no effect onMAPK activation.
Comparisons between cells that were transfected with cDNA inserts and the
appropriate vector controls were also performed. As expected, when clone 1, which
was transfected with the SSTR2 receptor cDNA is compared to clone 6, which was
only transfected with the pTracer vector, it is evident that treatment of the cells with
the Sandostatin analog increasesMAPK activity in clone 1 (Figure 14).
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Figure 14. pTracer Expressing Clones. This figure compares clone 1, '.-vhich was
transfected with the SSTR2 receptor and clone 6, which was transfected with only
the pTracer vector, and is the vector control of clone 1, in both untreated and treated
cell lines. Cells were grown overnight in serum depleted medium and treated with
1 x 1o-6M Sandostatin for 5 minutes before being lysed. MAPK intensity is
reported as percent of control intensity of bands obtained with clone 8 cells.
Percent control represents an average of 3 replicates.
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When clones 4B and 4C, which were transfected with the SSTR2 receptor cDNA
and the dominant negative mutant SHP-1 phosphatase cDNA, and clone 5, which
was transfected with the SSTR2 receptor and the wild-type SHP-1 phosphatase, are
compared to clone 8, which was transfected with pTracer vector and the
pcDNA3. l(+) vector, it also appears evident that treatment of the cells with the
Sandostatin analog increases MAPK activity in all of the clones shown (Figure 15).
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Figure 15. Clones Expressing Both Vectors. This figure compares clones 4B and
4C, which were transfected with the SSTR2 receptor cDNA and the dominant
negative mutant SHP-1 phosphatase cDNA, and clone 5, which was transfected
with the SSTR'> receptor cDNA and the wild-type SHP-1 phosphatase cDNA, to
clone 8, which was transfected with both the pTracer vector and the pcDNA3 .1(+)
vector, and is the vector control for clones 4B, 4C, and 5, in both untreated and
treated cell lines. Cells \.Vere grown overnight in serum depleted medium and
treated with 1 x 1 o-6M Sandostatin for 5 minutes before being lysed. MAPK
intensity is reported as percent of control intensity of bands obtained with clone 8
cells. Percent control represents an average of 3 replicates.
When clone 2, which was transfected with the dominant negative mutant SHP-1
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ph.osphatase cDNA., are comapared to clone 7, which was transfected with only the

pcDNAJ. l(+) vector, there does not appear to be a difference between untreated
MAPK levels and treated MAPK levels (Figure 16).
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Figure 16. pcDNAJ. l Expressing Clones. This figure compares clones 2, which
was transfected with the dominant negative mutant SHP-1 phosphatase cDNA, and
clone 3, which was transfected with the wild-type SHP-1 phosphatase cDNA, to
· clone 7, which was transfected with the pcDNA3. l(+) vector, and is the vector
control for both clones 2 and 3, in untreated and treated cell lines. Cells were grown
overnight in serum depleted medium and treated with 1 x 1o·6M Sandostatin for 5
minutes before being lysed. MAPK intensity is reported as percent of control
intensity of bands obtained with clone 8 cells. Percent control represents an
average of 3 replicates.
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DISCUSSION
SMS is a neuropeptide produced throughout the body. It has a variety of
functions, but one of its most unique characteristics is its ability to inhibit the
growth and secretion of compounds from cells that express its receptors. The
antiproliferative effects of SMS make it a candidate for chemotherapeutic therapies
in diseases such as cancer however, due to its extremely short half-life, its
effectiveness is severely limited.
Agonsits of SMS have been designed to eclipse this problem, and are
currently being used in the treatment of specific types of cancers. These agonsists
are designed to maintain the biologically active amino acids tryptophan and lysine
that are known to be necessary for binding to the SMS receptor. They are also
designed to have characteristics of longer half-lifes and greater binding affinities
towards specific receptors.
Exactly how SMS or any of its analogs work is yet to be determined, but it
is known that one of the five G protein coupled SSTR's must be present on the cell
surface Fugii et al., 1994). There is also evidence that the protein tyrosine
phosphatase SHP-1 may play a vital role in deactivating secondary signaling
molecules and their associated signal transduction pathways (Yi et al., 1993). What
these signals are, and how they work, is as of today still largely unknown.
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However, the SHP-1 protein has been shown to bind intracellularly to the SMS
receptor SSTR2 (Lopez et al., 1994), and appears to be good candidate for
controlling cellular proliferation and gastric secretions within the SMS signaling
pathway as this phosphatase can act on a variety of growth factor receptors (Liebow
et al, 1989). To determine if the wild-type SHP-1 protein plays a regulatory role in
the signal transduction pathway ofSMS and its analog Sandostatin, I cotransfected
the SSTR2 receptor along with a dominant negative mutant SHP-1 phosphatase into
wild-type NIH-3T3 cells, which do not normally express the SSTR2 receptor, and
analysed the growth properties and state ofMAPK activation of these cells.
Northern blot analyses oftotal cellular RNA demonstrated that clones
transcribed the SSTR2 cDNA at differential levels. Some of these same clones
were also shown to produce the wild-type SHP-1 phosphatase mRNA or the
dominant negative mutant SHP-1 phosphatase mRNA. Clones 1, 4B, 4C, and 5
were all shown to be able to transcribe the transfected SSTR2 receptor cDNA.
Clone 4B expressed the SSTR2 receptor at higher levels than did clone 4C. The
differential expression ofSSTR2 in clones 4B and 4C presented an opportunity to
study the effects ofhigh and low receptor expression on both cellular proliferation
and MAPK activity.
To determine if the wild-type SHP-1 phosphatase gene product regulated
cellular proliferation within the SMS pathway cells were grown in various
treatments. Results showed that clone 1, which was transfected with the SSTR2
receptor cDNA, had a decreased growth rate that was equal to 32% of the control
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cell line (Figure 9). This was statistically significant (q-calculated =12.95, q
critical=4.735, a=0.05) and suggested that expression of the SSTR2 receptor alone
can control cellular proliferation, possibly by stimulating the production of
endogenous SMS. These results are in agreement with Buscail et al., (1996) who
examined the differential mRNA expression of the five SSTR's in primary tumors
or metastases from colorectal or exocrine pancreatic cancer patients. They were
able to demonstrate that the SSTR2 receptor was present in normal pancreatic
tissues but was absent in exocrine pancreatic carcinomas and their metastases.
Therefore, it appears that just the absence of the SSTR2 receptor can benefit cells in
terms of proliferation as cell lines that express the SSTR2 receptor, such as clone 1,
have significantly decreased growth rates.
Delesque et al., (1997) demonstrated that when human SSTR2 cDNA was
transfected into pancreatic cancer cells (Capan-I and BxPC-3), which do not
express the SSTR2 receptor, cell growth was suppressed by up to 41% after 5 days.
They went on to show that cells which were transfected with the SSTR2 receptor
were able to increase SMSmRNA levels resulting in an increase in the production
and secretion of SMS-14.
Clone 2, which was transfected with the dominant negative mutant SHP-1
phosphatase cDNA alone, and therefore should not stimulate SMSproduction,
showed a decrease of 62 % in cellular proliferation (q-calculated=5.37, q
critical=4.735, a=0.05) and clone 3, which was transfected with only the wild-type
SHP-1 phosphatase cDNA, showed an increase of 24% (q-critical > q-calculated)

48
when compared to control cells (Figure 9). The results with clone 2 were
statistically significant and showed that cells needed the SHP-1 protein to
proliferate normally, and the dominant negative mutant SHP-1 phosphatase protein
decreased cell counts. This demonstrates that the SHP-1 protein does play an active
role in transmitting the SMS signal.
Clone 4B, which showed a high level of expression of the SSTR2 receptor
and also expressed the dominant negative mutant SHP-1 phosphatase, showed a
growth rate equal to 43% of control cells (Figure 9) and was statistically significant
(q-calculated=8.02, q-critical=4.735, a=0.05). Clone 4C, which expressed the
SSTR2 receptor at lower levels and also expressed the dominant negative mutant
SHP-1 phosphatase protein, showed a growth rate almost equal to 97% of the
control cells (Figure 9) and was shown to have no effect (q-critical > q-calculated)
on cellular proliferation. These results demonstrate that coexpression of the SSTR2
receptor and the dominant negative mutant SHP-1 phosphatase does not have an
additive effect upon cellular proliferation, as the expression of the SSTR2 receptor
decreases cellular growth more than the coexpression of the two cDNA's together.
Clone 5, which was transfected with the SSTR2 receptor cDNA and the
wild-type SHP-1 phosphatase cDNA, decreased cellular proliferation to 36% of
control cells (Figu re 9) and was statistically significant (q-calculated=8.94, q
critical=4.735, a=0.05). As was the case for clone 4B, which expressed the SSTR2
receptor at high levels along with the dominant negative mutant SHP-1 phosphatase
protein, and clone 4C, which expressed the SSTR2 receptor at low levels along with

the dominant negative mutant SHP-1 phosphatase protein, clone 5 also does not
show an additive effect as its cellular proliferation levels are almost equal to those
of clone 1, which expressed the SSTR2 receptor (Figure 9). Overexpression of the
wild-type SHP-1 protein does not appear to increase cell numbers within clone 5,
and therefore, it appears that the SSTR2 receptor has a larger influence on cellular
proliferation than does the wild-type SHP-1 protein.
The clones that were transfected with only one or both vectors, clones 6-8,
also tendend to reduce cell numbers (Figure 9). It is not understood what direct
effect the vectors themselves were having upon cellular proliferation however, it
was significant for clone 6, which was tranfected with the pTracer vector (q
calculated=7.34, q-critical=4.735, a=0.05) and clone 8, which was transfected with
the pTracer vector and the pcDNA3. l vector (q-calculated= S.34, q-critical=4.735,
a=0.05). It is possible that cellular proliferation was also dependent upon the
location of incorporation of the plasmid(s) into the cell's genome. Incorporation at
specific sites may have accounted for the decreases in cellular proliferation seen
within the clones. It is also possible, although not likely, that the vectors
themselves were, in someway, directly controlling cellular proliferation. This
seems improbable because these effects have not been seen in other cells
transfected with these vectors (data not shown).
In an attempt to determine if the SMS analog Sandostatin could affect the
growth rates of cells expressing the transfected genes, the cells were treated with 1
x 10-6M Sandostatin for 5 minutes after growth overnight in serum depleted
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medium. The results showed that the Sandostatin analog did not substantially affect
the growth rates of these clones (Figure 9). This data is inconsistent with results
published by Lopez et al., (1997). Their results showed that the analog did decrease
cellular proliferation by up to 39% in CHO cells transfected with the SSTR2
receptor cDNA and the wild-type SHP-1 phosphatase· cDNA when compared to
controls. When cellular proliferation studies were performed using, DMEM
I

supplemented with 10% CS, all clonal growth was similar toLopez et al., (1997)
(data not shown). The clones, which were transfected with the SSTR2 receptor
cDNA and the dominant negative mutant SHP-1 phosphatase cDNA, had higher
cell counts (38%) when compared to clones which were transfected with the SSTR2
receptor cDNA and the wild-type SHP-1 phosphatase cDNA. These cells were
initially treated with Sandostatin at the time of plating and were then trypsinized
and subsequently counted at 72 and 120 hours. However, concern about effects
caused by endogenous growth factors within the serum led me to perform these
tests under serum depleted conditions. These results do agree with those ofLiebow
et al., (1989), who showed that Sandostatin does not have an effect on the growth
inhibition of serum starved Mia PaCa-2 cells.
To determine if any of these clones have either a positive or negative effect
upon MAPK activation MAPK phosphorylation assays were performed. Data from
untreated cells showed that clone 1, which was transfected with the SSTR2 receptor
cDNA, depleted activated MAPK to less than detectable levels, and was
significantly different (p=0.009, a=0.05) from NIH-3T3 control cells (Figure 10).
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Clone 2, which was transfected with the dominant negative mutant SHP-1
phosphatase cDNA, decreased MAPK activity to 62% of the NIH-3T3 control cells
(Figure 10) and was shown to have no effect (p=0. l, a=0.05). Clone 3, which was
transfected with the wild-type SHP-1 phosphatase cDNA, was also shown to have
no effect (p=0.808, a=0.05) upon MAPK activity (Figure 10).
This data correlated well with the cell count data. When the SSTR2
receptor cDNA was transfected alone into NIH-3T3 cells, cell counts decreased and
MAPK activity fell to below detectable levels. The transfection of the dominant
negative mutant SHP-1 phosphatase into NIH-3T3 cells was also capable of
decreasing cell counts and MAPK activity, but not to the levels seen by transfection
of the SSTR2 receptor alone. An overexpression of wild-type SHP-1 phosphatase
·in these clones increased cell counts and slightly increased MAPK activity.
When the SSTR2 receptor cDNA was transfected into NIH-3T3 cells along
with the dominant negative mutant SHP-1 phosphatase the same effects occured as
in the cellular proliferation assays. Clone 4B, which was transfected with the
SSTR2 receptor at high levels along with the mutant SHP-1 protein, reduced
MAPK activity to levels that were 26% of the NIH-3T3 control cells (Figure 10)
and showed significant difference (p=0.0447, a=0.05), while clone 4C, which
expressed the SSTR2 receptor at low levels along with the mutant SHP-1 protein,
only reduced MAPK activity to 53% of the NIH-3T3 control cells (Figure 10) and
showed no effect (p=0.0957, a=0.05). These results however do appear to at least
be partially additive, unlike the cell counts. MAPK activity was decreased to a
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greater extent in cells that were transfected with the SSTR2 receptor cDNA and the
dominant negative mutant SHP-1 phosphatase cDNA than in cells that were
transfected with the dominant negative mutant SHP-1phosphatase cDNA. They are
not however decreased to levels that are undetectable, as is the case for clone 1,
which was transfected with the SSTR2 receptor cDNA. This suggests that the wild
type SHP-1 phosphatase played a role in the activation of MAPK by SMS, although
we are not sure to what extent. It appears that the dominant negative mutant SHP-1
phosphatase is somehow interfering with the normal role of the SSTR2 receptor.
The transfection of the wild-type SHP-1 phosphatase cDNA, when
transfected along with the SSTR2 receptor, as in clone 5, stimulated MAPK activity
to levels that were 86% of the NIH-3T3 control cells (Figure 10) and had no effect
(p=0.0906) on MAPK activity. This was interesting because as MAPK activity was
increasing in this clone its cellular proliferation was decreasing to levels resembling
clone 1, which was transfected with the SSTR2 receptor cDNA. This suggests that
the overexpression of wild-type SHP-1 phosphatase inactivated some of the MAPK
activity, and that this inactivation decreased cellular proliferation. This was also
evident in clone 6, which was transfected with the pTracer vector, where the
decrease in cellular proliferation (Figure 9) was associated with a decrease in
MAPK activity (Figure 10) and was significantly different (p=0.0221, a=0.05), not
however to the extent seen in clone 1, which was transfected with the SSTR2
receptor cDNA, and 4B, which was transfected with the SSTR2 receptor cDNA
along with the dominant negative mutant SHP-1 phosphatase cDNA. The reason
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behind the clone 6 decrease in cellular proliferation and MAPK activity was not
clear, and these correlations were not consistent with clone 7, which was transfected
with the pcDNA3.1 vector, and clone 8, which was transfected with both the
pTracer vector and the pcDNA3. l vector. Both of these clones showed MAPK
activity levels that were similar to the NIH-3T3 control cells (Figure 10) and
statistically different (p=0.585,:a=0.05 and p=0.812, a=0.05 respectively). Both,
however, showed decreased cellular proliferation, especially clone 8.
When the clones were treated with the Sandostatin analog under serum
depleted conditions the results seemed to be varied. The MAPK activity level of
clone 1, which was transfected with the SSTR2 receptor cDNA, increased from
below background levels in untreated cells to 58% of the treated NIH-3T3 control
cells (Figure 11). Clone 2, which was transfected with the dominant negative
mutant SHP-1 phosphatase cDNA, decreased MAPK activation levels to 44% ofthe
treated NIH-3T3 control cells (Figure 1 I). Clone 3, which was transfected with the
wild-type SHP-1 phosphatase cDNA, showed MAPK activation levels of 85% of
the treated NIH-3T3 control cells (Figure 11). Clones 4B, and 4C, both of which
were transfected with the SSTR2 receptor cDNA along with the dominant negative
mutant SHP-1 phosphatase cDNA, showed MAPK activation levels equal to 800/o
and 92% of treated NIH-3T3 control cells respectively (Figure 11). Clone 5, which
was transfected with the SSTR2·receptor cDNA and the wild-type SHP-1
phosphatase cDNA, showed MAPK activation levels equal to 79% of treated NIH3T3 control cells (Figure 11). Clone 6, which was transfected with the pTracer
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vector, showed MAPK activation levels equal to 87% of treated N!H-3T3 control
cells (Figure 11). Clone 7, which was transfected with the the pcDNA3.1 vector,
and clone 8, which was transfected with both the pTracer vector and the
pcDNA3.1(+) vector, showed MAPK activation levels equal to 54% and 55% of
the treated NIH-3T3 control cells respectively (Figure 11). Overall, all of the
.
clones treated with the Sandostatin
analog were found to have no effect on MAPK

activation levels (p > 0.05, a=0.05) when compared to the treated NIH-3T3 control
cells. This correlates well with the cellular proliferation data which also showed
that Sandostatin only significantly affected clone 1, which was transfected with the
SSTR2 receptor cDNA, and clone 5, which was transfected with the SSTR2
receptor cDNA and the wild-type SHP-1 cDNA.
When the clones are compared to their respective control vectors a trend
begins to appear. Treatment with the Sandostatin analog increases MAPK activity
in clones that were transfected with the SSTR2 receptor cDNA (clones 1,4B,4C,
and 5) (Figures 14 and 15) much more than it does in the clones which were not
transfected with the SSTR2 receptor (clones 2 and 3) (Figure 16). Clone 1, which
was transfected with the SSTR2 receptor cDNA, under no treatment was 0% of its
control vector clone, clone 6, which was transfected with the pTracer vector. Upon
treatment with the Sandostatin analog MAPK activity in clone 1 increased to 67%
of its control vector clone 6. Clones 4B and 4C, which were transfected with the
SSTR2 receptor cDNA and the dominant negative mutant SHP-1 phosphatase
cDNA, increased their MAPK activity from 25% and 52% respectively to 147%
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and 171% also respectively when treated with the Sandostatin analog. Clone 5,
which was transfected with the SSTR2 receptor cDNA and the wild-type SHP-1
cDNA, also increased its MAPK activity from 88% to 147% when treated with the
Sandostatin analog. Clone 2, which was transfected with the dominant negative
mutant SHP-1 phosphatase cDNA, and clone 3, which was transfected with the
wild-type SHP-1 phosphatase cDNA, decreased their MAPK activity from 65% and
113% respectively to 55% and 107% also respectively. This data shows that only
the clones which were transfected with the SSTR2 receptor cDNA showed
increases in MAPK activity. Therefore, it appears that the Sandostatin analog
increases MAPK activity when the SSTR2 receptor is expressed, and tends to
decrease it when the receptor is not expressed. Sandostatin does not appear to be
able to affect MAPK activity through the wild-type SHP-1 phosphatase.
It is known that the SHP-1 protein is recruited to activated growth factor
receptors and causes a transient dephosphorylation and inactivation of specifically
associated signaling molecules Fugii et al., (1994), and it has been postulated by
Lopez et al., (1997) that the rapid activation of the SHP-1 protein following SMS
stimulation of cells is the initiating step for SSTR2 signal transduction that leads to
growth inhibition. These data tend to support Lopez et al., (1997), however not
directly, as they indicate SHP-1 works independently of the SSTR2 receptor in
controlling cell growth as expression of the dominant negative mutant SHP-1
phosphatase protein can reduce cell growth on its own. Expression of the SSTR2
receptor, especially at high levels, however, appears to be the largest factor
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regulating cellular proliferation in the NIH-3T3 mouse fibroblast cells whether or
not cells were stimulated with Sandostatin, but the SSTR2 receptor and the SHP-1
protein however, do appear to cooperate in regulating MAPK activation. Therefore,
it appears that SMS can partially regulate cell growth through the SHP-1 protein,
but that the SSTR2 receptor and the deactivation of MAPK have a greater effect.
This data has also shown that the Sandostatin does not work through the exact same
mechanism that SMS does. Instead, it appears that Sandostatin regulates its cellular
proliferation through the SHP-1 protein.
In conclusion this data suggests that the SSTR2 receptor does control
cellular proliferation, and that this control was somehow regulated through the
MAPK pathway. The SHP-1 protein also appears to be involved in cellular
proliferation as its inhibition by a dominant negative mutant SHP-1 phosphatase
drastically reduced cell counts. This data also suggests that the SHP-1 protein is
involved in signaling through the MAPK pathway as the dominant negative mutant
SHP-1 protein was able to decrease MAPK activation. However, it does not appear
that the SSTR2 receptor and the SHP-1 protein are able to cooperate in regulating
cellular proliferation. This is shown when the SSTR2 receptor and the wild-type
SHP-1 protein are cotransfected into NIH-3T3 cells. Here, cellular proliferation
does not decrease to the levels seen in clones that only express one of the proteins.
However, the two proteins do appear to cooperate, at least in part, to control MAPK
activation.
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This data also suggests that treatment of the clones with the SMS analog
Sandostatin does not affect cellular proliferation in any of the clones. It does
however appear to affect MAPK activation as clones that were transfected with the
SSTR2 receptor cDNA, either alone or with the dominant negative mutant SHP1 phosphatase cDNA, increased MAPK activation.
Future experiments to determine if the MAPK pathway is directly affected
by SMS or Sandostatin is to look at the possible roles of the adapter protein She. It
would also be of interest to determine if different expression levels of the SSTR2
receptor influence expression levels of SMS, and if the rate of SMS secretion can be
manipulated by expressing the mutant SHP-1 protein.
It will be a long time before a good part of the signaling pathway of SMS
and its analogs are well understood, however manipulation of this pathway offers a
good possibility of alleviating some of the symptoms common in several major
diseases like diabetes, and specific forms of cancer.
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